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ABSTRACT
ObjeCtives
To evaluate the efficacy and safety of endovascular 
treatment, particularly adjunctive intra-arterial 
mechanical thrombectomy, in patients with ischaemic 
stroke.
Design
Systematic review and meta-analysis.
Data sOurCes
Medline, Embase, Cochrane Central Register of 
Controlled Trials, Web of Science, SciELO, LILACS, and 
clinical trial registries from inception to December 
2015. Reference lists were crosschecked.
eligibility Criteria fOr seleCting stuDies
Randomised controlled trials in adults aged 18 or more 
with ischaemic stroke comparing endovascular 
treatment, including thrombectomy, with medical care 
alone, including intravenous recombinant tissue 
plasminogen activator (rt-PA). Trial endpoints were 
functional outcome (modified Rankin scale scores of 
≤2) and mortality at 90 days after onset of symptoms. 
No language or time restrictions applied.
results
10 randomised controlled trials (n=2925) were 
included. In pooled analysis endovascular treatment, 
including thrombectomy, was associated with a higher 
proportion of patients experiencing good (modified 
Rankin scale scores ≤2) and excellent (scores ≤1) 
outcomes 90 days after stroke, without differences in 
mortality or rates for symptomatic intracranial 
haemorrhage, compared with patients randomised to 
medical care alone, including intravenous rt-PA. 
Heterogeneity was high among studies. The more 
recent studies (seven randomised controlled trials, 
published or presented in 2015) proved better suited 
to evaluate the effect of adjunctive intra-arterial 
mechanical thrombectomy on its index disease owing 
to more accurate patient selection, intravenous rt-PA 
being administered at a higher rate and earlier, and 
the use of more efficient thrombectomy devices. In 
most of these studies, more than 86% of the patients 
were treated with stent retrievers, and rates of 
recanalisation were higher (>58%) than previously 
reported. Subgroup analysis of these seven studies 
yielded a risk ratio of 1.56 (95% confidence interval 
1.38 to 1.75) for good functional outcomes and 0.86 
(0.69 to 1.06) for mortality, without heterogeneity 
among the results of the studies. All trials were open 
label. Risk of bias was moderate across studies. The 
full results of two trials are yet to be published.
COnClusiOns
Moderate to high quality evidence suggests that 
compared with medical care alone in a selected group 
of patients endovascular thrombectomy as add-on to 
intravenous thrombolysis performed within six to 
eight hours after large vessel ischaemic stroke in 
the anterior circulation provides beneficial functional 
outcomes, without increased detrimental effects.
systematiC review registratiOn
PROSPERO CRD42015019340.
Introduction
Stroke is the second leading cause of death worldwide,1 
its incidence is rising in those aged less than 75 years,2 
and the global burden attributable to stroke is increas-
ing.3 Along with preventive measures, effective treat-
ments are therefore needed to reduce the deleterious 
consequences of stroke.
Arterial occlusion is the cause of ischaemic stroke. 
Over time, deprivation of blood leads to progressive cell 
death. Early reversal of vascular occlusion limits the vol-
ume of damaged tissue and correlates with outcome.4 
By achieving timely reperfusion, thrombolysis improves 
functional recovery, but only in 33% of patients.5 6  Fur-
thermore, the recanalisation rates associated with intra-
venous recombinant tissue plasminogen activator 
(rt-PA)—approximately 46%7—are not ideal, and the use 
of endovascular interventions may reverse vessel occlu-
sion more effectively and thus help further improve out-
comes. Both drug and mechanical endovascular 
interventions have been evaluated in acute ischaemic 
stroke. Thrombectomy can be performed using devices 
that disrupt, aspirate, or retrieve clots. The procedure 
can be used alone or as an add-on to intravenous or 
intra-arterial chemical thrombolysis—that is, adjunctive 
intra-arterial mechanical thrombectomy.
Results for adjunctive intra-arterial mechanical 
thrombectomy from published randomised controlled 
WhAT IS AlReAdy knoWn on ThIS TopIC
Intravenous thrombolysis is the standard treatment for acute ischaemic stroke, but 
the rates for recanalisation are not ideal
The use of concomitant endovascular reperfusion techniques, such as adjunctive 
intra-arterial mechanical thrombectomy, may help to improve clinical outcomes further
WhAT ThIS STudy AddS
This systematic review and meta-analysis of 10 randomised controlled trials provide 
moderate to high quality evidence suggesting that, in carefully selected patients 
endovascular treatment, particularly adjunctive intra-arterial mechanical 
thrombectomy, provided within six to eight hours after ischaemic stroke involving 
large vessels in the anterior circulation, leads to improved functional outcomes at 
90 days without increased mortality or symptomatic intracerebral haemorrhage
This evidence supports the need to restructure current neurointerventional 
resources and to change clinical practice
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trials are heterogeneous, and the clinical benefit of 
the procedure are uncertain.8-11 We conducted a sys-
tematic review with meta-analysis to compare the 
efficacy and safety of endovascular treatment (in 
 particular adjunctive intra-arterial mechanical 
thrombectomy) with standard medical care alone 
(in particular intravenous rt-PA) in adults with isch-
aemic stroke.
Methods
Protocol and guidance
The study protocol was reported following PRIMA-P 
guidelines12  and was registered at PROSPERO. The 
methods and reporting of the systematic review 
 followed PRISMA13  guidelines. Reporting of statistical 
data followed SAMPL14 guidelines.
eligibility criteria
We included randomised controlled trials reporting on 
the efficacy and safety of adjunctive intra-arterial 
mechanical thrombectomy, independently of the device 
used, compared with medical care alone, including 
intravenous rt-PA for ischaemic stroke in adults (≥18 
years). To be included, studies had to mention func-
tional outcome and mortality at 90 days after symptom 
onset as trial endpoints. We did not exclude studies a 
priori owing to poor quality, language, or time restric-
tions, but we excluded observational, non-controlled, 
or non-randomised interventional studies. Since our 
primary aim was to evaluate adjunctive intra-arterial 
mechanical thrombectomy compared with intravenous 
rt-PA, we excluded randomised controlled trials in 
which patients were not submitted to mechanical 
thrombectomy in the experimental arm (for example, 
trials only evaluating patients submitted to other types 
of endovascular treatment, such as intra-arterial rt-PA 
and urokinase-type plasminogen activator) or in which 
patients were not submitted to intravenous rt-PA in the 
control arm.
information sources and search strategy
Electronic identification of reports was conducted in 
Medline, Embase, Cochrane Central Register of Con-
trolled Trials, Web of Science, SciELO, and LILACS. 
Grey literature was searched through appropriate 
databases (OpenGrey, Database of Abstracts of 
Reviews of Effects, British Library Thesis Service). 
We also consulted clinical trial registries (ClinicalTri-
als.gov, European Union Clinical Trials Register, 
World Health Organization International Clinical 
 Trials Registry Platform, ISRCTN Registry, Stroke 
 Trials Registry). The last electronic search was on 
14 December 2015.
We also cross checked the references of potentially 
eligible randomised controlled trials.
For the search strategy we combined the terms (cere-
brovascular disorder OR stroke) with (mechanical 
thrombolysis OR embolectomy OR thrombectomy). The 
Cochrane highly sensitive search strategy was used to 
retrieve randomised controlled trials (see supplemen-
tary file S1 for details of the search strategy).15
study selection
Two reviewers (FBR, JBN) independently screened the 
titles and abstracts of retrieved reports for potential eli-
gibility. They then screened the full text of potentially 
relevant trials. Disagreements were resolved by consen-
sus or with the help of a third reviewer (DC). Interob-
server bias (the percentage of agreement achieved) was 
calculated.16
Data collection process
Two reviewers (FBR, JBN) independently extracted data 
from the included randomised controlled trials using a 
standardised electronic form. Disagreements were 
resolved by consensus or with the help of a third 
reviewer (DC). Another reviewer (JC) double checked 
the extracted data. When possible we used data from 
intention to treat populations. When such data were not 
available, we used data from modified intention to treat 
populations, defined as participants who were included 
and completed the study (that is, some initially ran-
domised who were excluded from analysis) regardless 
of compliance with the allocated interventions. We 
extracted per protocol data only when data from inten-
tion to treat or modified intention to treat populations 
were unavailable.
Outcomes and prioritisation
The primary efficacy outcome was the proportion of 
patients achieving a good functional outcome at 90 
days after the onset of symptoms, defined as a modified 
Rankin scale17  score between 0 and 2, representing 
functional independence. The primary safety outcome 
was all cause mortality at 90 days. The secondary effi-
cacy outcome was the proportion of patients achieving 
an excellent functional outcome at 90 days (modified 
Rankin scale score ≤1). The secondary safety outcome 
was the proportion of patients with symptomatic intra-
cerebral haemorrhage as defined in the Safe Implemen-
tation of Thrombolysis in Stroke-Monitoring Study 
(SITS-MOST) study.18 When symptomatic intracerebral 
haemorrhage was not defined using SITS-MOST crite-
ria, we accepted other definitions.
risk of bias in individual studies
Two reviewers (FBR, JBN) independently assessed the 
risk of bias of individual studies using the Cochrane 
Collaboration risk of bias tool.15 Three additional crite-
ria were sought: independent funding, early stopping of 
trial, and clinical trial registration to determine whether 
the trial was retrospectively or prospectively registered. 
If a trial was retrospectively registered, we considered 
the risk of bias to be high because of the risk of report-
ing bias.
Data synthesis
We used random effects meta-analyses (RevMan 5.3.3 
software) weighted by the inverse variance method to 
estimate pooled risk ratios and 95% confidence inter-
vals. When using the Mantel-Haenszel method we con-
sidered sample size and event rates. We chose risk 
ratios as effect measures owing to the greater similarity 
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of relative estimates between studies with different 
designs, populations, and lengths of follow-up.19 Raw 
data were converted to risk ratios. We assessed hetero-
geneity with the Cochran Q test and the I2 test.20 When 
statistically significant differences in risk were found 
(P<0.05), we also determined absolute effects and 
derived the additional number of participants with 
events per 1000 who benefitted or experienced harm 
from receiving the studied intervention.
To explore whether cumulative data were adequately 
powered to evaluate outcomes, we carried out trial 
sequential analyses for primary outcomes using TSA 
version 0.9 beta (Copenhagen Trial Unit, Centre for Clin-
ical Intervention Research, Copenhagen, Denmark, 
2011).21 22  We calculated the required information size 
and computed the trial sequential monitoring boundar-
ies using the O’Brien-Fleming approach.23 Our analysis 
was based on a two sided 5% risk of a type I error, 20% 
risk of a type II error (power of 80%), risk reduction 
based on pooled analysis, the weighted incidence of 
events in the control group, and heterogeneity. Power of 
the primary outcomes findings was interpreted if statis-
tical significance was reached with either a minimum 
sample size or crossing a trial sequential alpha spend-
ing monitoring boundary. Trial sequential analysis 
evaluates whether statistically significant results of 
meta-analysis are reliable, taking into account informa-
tion size (number of participants in the meta-analysis 
required to accept or reject a prespecified intervention 
effect). The technique is analogous to sequential moni-
toring boundaries in a single trial. Trial sequential anal-
ysis adjusts the threshold of statistical significance and 
may reduce the risk of random errors due to repetitive 
testing of accumulating data.
Because of inequalities in trial design, including 
patient populations and interventions,24 we present 
data separately for all outcomes a priori according to 
the year of publication or the presentation of the trial 
results (2013 and 2015). We planned further subgroup 
analyses for sex, trials with different risk of bias, throm-
bectomy devices (≥85% v <85% rate of stent retriever 
use), time to treatment, the administering of intrave-
nous rt-PA, and characteristics of stroke. We carried out 
a sensitivity analysis by excluding data from unpub-
lished trials.
meta-biases
If more than 10 studies were available for each out-
come, we assessed publication bias by visual inspec-
tion of asymmetry in funnel plots.15  We also carried out 
Egger’s and Peters’ tests.25 26
Confidence in cumulative evidence
We evaluated the quality of evidence using the grading 
of recommendations assessment, development and 
evaluation (GRADE) working group methods.27
Results
study selection
Electronic searches yielded 758 records after removal of 
duplicates. The interobserver agreement between 
screeners was good (Cohen’s κ coefficient 0.75, 95% 
confidence interval 0.56 to 0.93).16  Ten studies were 
included (fig 1 ); three published in 2013 (Interventional 
Management of Stroke (IMS) III Trial (IMS III), Intra-ar-
terial Versus Systemic Thrombolysis for Acute Ischemic 
Stroke (SYNTHESIS Expansion), Mechanical Retrieval 
and Recanalization of Stroke Clots Using Embolectomy 
(MR RESCUE)),28-30  five in 2015 (Endovascular treat-
ment for acute ischemic stroke in the Netherlands (MR 
CLEAN), Endovascular Treatment for Small Core and 
Proximal Occlusion Ischemic Stroke (ESCAPE), Extend-
ing the Time for Thrombolysis in Emergency Neurologi-
cal Deficits-Intra-Arterial (EXTEND-IA), Solitaire With 
the Intention For Thrombectomy as PRIMary Endovas-
cular Treatment (SWIFT-PRIME), and Endovascular 
Revascularization With Solitaire Device Versus Best 
Medical Therapy in Anterior Circulation Stroke Within 
8 Hours (REVASCAT)),31-35 and two presented in 2015 but 
not yet published (Assess the Penumbra System in the 
Treatment of Acute Stroke (THERAPY) and Trial and 
Cost Effectiveness Evaluation of Intra-arterial Throm-
bectomy in Acute Ischemic Stroke (THRACE)).36 37  When 
needed, we consulted the published protocols, supple-
mentary material, and press releases of these stud-
ies.38-47 The principal investigators of THERAPY and 
THRACE were unsuccessfully contacted for data. There-
fore, data extraction for these trials was based solely on 
results presented at scientific meetings and in press 
releases.
study characteristics
All studies were multicentre, parallel, prospective ran-
domised open blinded endpoint clinical trials (table 1). 
All but four (SYNTHESIS, MR CLEAN, REVASCAT, and 
THRACE) were international. The number of partici-
pants ranged from 70 to 656. Overall, the studies 
involved 2925 participants—1564 in the endovascular 
treatment arm and 1361 in the standard medical care 
(intravenous thrombolysis) arm, based on either an 
intention to treat population or a modified intention to 
treat population.
The main inclusion criteria were adults after stroke with 
time from symptom onset to intravenous thrombolysis of 
Records screened aer duplicates removed (n=801)
Full text articles assessed for eligibility (n=10)
Studies included in qualitative synthesis (n=10)
Studies included in quantitative synthesis (meta-analysis) (n=10)
Records identied
through database
searching (n=758)
Additional records
identied through
trials registries (n=42)
Additional record identied
through conference
proceedings (n=1)
Records excluded (n=791)
Full text articles excluded (n=0)
fig 1 | study flow selection
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3 to 4.5 hours and time from symptom onset to endo-
vascular treatment between 5 and 12 hours. In contrast 
with IMS III, SYNTHESIS, EXTEND-IA, SWIFT-PRIME, 
THERAPY, and THRACE trials, which only included 
patients who were also treated with intravenous rt-PA, 
some trials (MR RESCUE, MR CLEAN, ESCAPE, and 
REVASCAT) included patients who were not eligible for 
intravenous thrombolysis.
All the studies focused on strokes involving the ante-
rior circulation, although IMS III, SYNTHESIS, and 
THRACE also allowed strokes involving the posterior 
circulation. MR RESCUE, ESCAPE, EXTEND-IA, MR 
CLEAN, and THERAPY included strokes within the loca-
tion of the internal carotid artery and/or M1 and/or M2 
portions of the middle cerebral artery, whereas SWIFT-
PRIME, REVASCAT, and THRACE included only strokes 
involving the internal carotid or M1. The Alberta Pro-
gram Stroke Early Computed Tomography Score 
(ASPECTS) was also an enrolment criterion in IMS III, 
ESCAPE, SWIFT PRIME, and REVASCAT (see supple-
mentary table S1). Radiological confirmation of large 
vessel occlusion was an inclusion criterion in all 2015 
studies. This was not the case in trials done in 2013 (IMS 
III, SYNTHESIS, and MR RESCUE). Perfusion imaging 
depicting potentially salvageable brain tissue was only 
a requirement for patient inclusion in ESCAPE, 
EXTEND-IA, and SWIFT-PRIME.
The baseline characteristics of included patients 
were similar between arms across studies (table 2). 
Mean age ranged from 62 to 71 years, and sex distribu-
tion was approximately 1:1 in all studies. The severity of 
stroke ranged from 13 to 19 points (moderate, to moder-
ate to severe stroke severity) in the National Institute of 
Health stroke scale.
All studies evaluated endovascular treatment (with 
or without intravenous rt-PA) compared with standard 
medical treatment—namely, intravenous rt-PA (table 3). 
In the intervention arm, use of thrombolysis (intrave-
nous rt-PA) ranged from 0% in SYNTHESIS to 100% in 
IMS III, EXTEND-IA, SWIFT PRIME, THERAPY, and 
THRACE. In SYNTHESIS, intravenous rt-PA was not 
administered owing to the study design (the study com-
pared endovascular treatments, such as intra-arterial 
rt-PA and thrombectomy, with intravenous thromboly-
sis). In IMS III, the study design contemplated a 
planned dose reduction in intravenous rt-PA in the 
thrombectomy arm owing to intra-arterial rt-PA being 
administered concomitantly. Intravenous rt-PA was 
administered in the control arms (standard medical 
treatment) of all studies. However, in MR RESCUE, only 
28.1% of patients received intravenous thrombolysis 
because they were considered unsuitable candidates. 
In the other trials, 77% to 100% of the patients in the 
medical care arm received intravenous rt-PA.
All the studies included thrombectomy as an endo-
vascular treatment option. About two thirds of the 
patients randomised to the intervention arm (64.1%) 
underwent thrombectomy. IMS III, MR RESCUE, SYN-
THESIS, and MR CLEAN allowed other endovascular 
interventions (intra-arterial rt-PA and urokinase-type 
plasminogen activator) in addition to thrombectomy; in t
ab
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SYNTHESIS and IMS III, only 30.9% and 39.2% of the 
patients were treated with adjunctive intra-arterial 
mechanical thrombectomy, respectively. In  SYNTHESIS, 
the intervention arm included intra-arterial thromboly-
sis with rt-PA, mechanical disruption or retrieval of 
clots, or a combination of these approaches. In IMS III, 
the intervention arm included thrombectomy or endo-
vascular delivery of rt-PA. In the other trials, 77.1% to 
91.5% of the patients in the intervention arm were 
treated with adjunctive intra-arterial mechanical 
thrombectomy (data on patients in the THERAPY and 
THRACE trials are not yet available).
The thrombectomy devices selected among the stud-
ies varied, and some studies used more than one device 
(see supplementary table S2). In the 2013 studies and 
THERAPY early generation devices were mostly used 
(such as Merci retriever, Penumbra system, other aspi-
ration systems, wire disruption), and only a small 
number of patients was treated with stent retrievers. 
Whereas in MR RESCUE and THERAPY no stent retriev-
ers were used, in IMS III and SYNTHESIS the rate of 
stent retriever use was low—2.9% and 41%, respec-
tively. However, among most 2015 studies the rate of 
stent retriever use (such as Solitaire FR, Solitaire 2, 
Trevo, Catch) was more than 86%. The time from acute 
stroke to endovascular treatment ranged from 225 to 
355 minutes.
In the intervention arm, recanalisation rates varied 
between 25.0% and 88.0% according to a score of ≥2b/3 
(perfusion of half or greater of the vascular distribution 
of the occluded artery) on the thrombolysis in cerebral 
infarction perfusion scale or modified thrombolysis in 
cerebral infarction perfusion scale (see supplementary 
table S3). SYNTHESIS did not report reperfusion rates. 
For THRACE, these data are still unavailable. Recanali-
sation rates greater than 58% were observed in MR 
CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, 
REVASCAT, and THERAPY. With the exception of partic-
ipants in the THERAPY trial, most (86.1% to 100%) of 
the patients in these last trials with higher recanalisa-
tion rates were treated with stent retrievers.
The follow-up period was 90 days in all the trials 
and all included data for our primary efficacy and 
safety outcomes. In IMS III, MR RESCUE, SYNTHESIS, 
and ESCAPE, symptomatic intracerebral haemorrhage 
was defined by the authors’ own criteria or according 
to previously defined criteria other than definition of 
the SITS-MOST study.18 In THRACE, the criteria used 
for symptomatic intracerebral haemorrhage is still 
unknown.
risk of bias within studies
The overall risk of bias was moderate among studies 
(fig 2). Random sequence generation, blinding of out-
come assessment, and selective reporting were consid-
ered as low risk items across studies. For THERAPY and 
THRACE, the bias associated with random sequence 
generation is not known owing to lack of information. 
Outcome assessment at 90 days was conducted in per-
son in ESCAPE, EXTEND-IA, and SWIFT-PRIME, in per-
son or by video visualisation in REVASCAT, by video t
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visualisation in THERAPY, and by telephone in SYN-
THESIS and MR CLEAN. IMS III and MR RESCUE did not 
report the method used for evaluation of outcome 
assessment—this information was absent from all avail-
able documents pertaining to both trials, including pro-
tocol and published and unpublished reports. This 
information is still unavailable for THRACE. Allocation 
concealment and blinding of participants and staff 
were classified as high risk owing to study design (that 
is, prospective randomised open blinded endpoint 
design). All the studies except for THRACE were at least 
partially funded by industry. SYNTHESIS, IMS III, and 
MR RESCUE were publicly funded but also had some 
support from industry. ESCAPE, MR CLEAN, 
EXTEND-IA, and REVASCAT had both mixed funding 
from governmental bodies and unrestricted grants from 
industry. SWIFT PRIME and THERAPY had only indus-
try support.
Six studies were stopped early—IMS III because of 
futility according to the interim analysis as per protocol, 
after 72.3% of the planned patients had been enrolled. 
The other five trials were stopped because of efficacy, 
after the publication of positive results in MR CLEAN: 
interim analyses were brought forward in ESCAPE 
(63.2% of the planned sample size), EXTEND-IA (70.0% 
of the planned sample size), and SWIFT PRIME (23.5% 
of the planned sample size), and enrolment was 
stopped because efficacy boundaries were met. In 
REVASCAT and THERAPY, indication of lack of equi-
poise led to enrolment being stopped before the efficacy 
boundary was reached—in REVASCAT after enrolling 
25.4% of the planned sample size and in THERAPY after 
enrolling 15.6% of the planned sample size.
One trial (MR RESCUE) was retrospectively registered 
in 2006, two years after the study start. Concerning 
attrition bias, IMS III and MR CLEAN showed 
 imbalances between withdrawals in the intervention 
and control arms. In MR RESCUE and REVASCAT, the 
lower number of participants between arms limited 
considerations about the effect of withdrawals on study 
results. Owing to lack of information for THRACE, attri-
tion bias was not evaluable.
synthesis of results
All studies, with the exception of THRACE (lacked 
details for modified Rankin scale score ≤1 and symp-
tomatic intracerebral haemorrhage), reported the 
sought outcomes (table 1  describes the primary out-
comes for each study). Results of individual studies 
were incorporated in forest plots (figures 3 and 4, and 
supplementary figures S1 and S2 and S5 to S7).
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fig 2 | risk of bias summary
table 3 | Characteristics of intervention within treatment arms
trial
both arms
 
aimt arm
 
medical care (iv rt-Pa) arm
no of 
patients*
no (%) iv 
rt-Pa
no of 
patients*
no (%) receiving 
thrombectomy
no (%) receiving 
iv rt-Pa
no (%) receiving 
ia rt-Pa
no (%) receiving 
thrombectomy+iv rt-Pa
no of 
patients*
no (%) of iv 
rt-Pa
IMS III28 656 656 (100)   434 170 (39.2) 434 (100)† 266 (61.3) 170 (39.2)   222 222 (100)
SYNTHESIS29 362 178 (49.2)   181 56 (30.9) 0 (0) 109 (60.2) 0 (0)/56 (30.9)‡   181 178 (98.3)
MR RESCUE30 127 44 (34.6)   70 61 (87.1) 28 (40.0) 8 (11.4) 28 (40.0)   57 16 (28.1)
MR CLEAN31 500 445 (89.0)   233 195 (83.7) 203 (87.1) 25 (10.7) NS   267 242 (90.6)
ESCAPE32 315 238 (75.6)   165 151 (91.5) 120 (72.7) NA 120 (72.7)   150 118 (78.7)
EXTEND-IA33 70 70 (100)   35 27 (77.1) 35 (100) NA 27 (77.1)   35 35 (100)
SWIFT PRIME34 191 191 (100)   98§ 87 (88.8)§ 98 (100)§ NA 87 (88.8)‡   93‡ 93 (100)§
REVASCAT35 206 150 (72.8)   103 98 (95.1) 70 (68.0) 1 (1.0) NS   103 80 (77.7)
THERAPY36 108 108 (100)   55 NS 55 (100) 0 (0.0) NS   53 53 (100)
THRACE37 385 385 (100)   190 NS 190 (100) 0 (0.0) NS   195 195 (100)
AIMT=adjuvant intra-arterial mechanical thrombolysis; IV=intravenous; IA=intra-arterial; NA=not applicable; NS=not specified; rt-PA=recombinant tissue plasminogen activator.
*Intention to treat population.
†Approximately two thirds of standard dose.
‡IA rt-PA.
§Modified intention to treat population.
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Overall, 1129 out of 2907 patients (38.8%) achieved a 
good functional outcome at 90 days. Patients receiving 
endovascular treatment had a higher chance of achiev-
ing a good outcome (risk ratio 1.37, 95% confidence 
interval 1.14 to 1.64; fig 3), with an increase of 123 
patients (95% confidence interval 46 to 212 patients) 
attaining a good outcome for each 1000 additional 
patients receiving endovascular treatment compared 
with medical care alone. Considerable statistical het-
erogeneity (I2=69%, P=0.0006) was present for overall 
2013
  IMS III
  MR RESCUE
  SYNTHESIS
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00, χ2=0.97, df=2, P=0.62, I2=0%
Test for overall eect: z=0.21, P=0.83
2015
  ESCAPE
  EXTEND-IA
  MR CLEAN
  SWIFT PRIME
  REVASCAT
  THERAPY
  THRACE
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00, χ2=5.98, df=6, P=0.43, I2=0%
Test for overall eect: z=7.24, P<0.001
Total (95% CI)
Test for heterogeneity: τ2=0.05, χ2=29.12, df=9, P<0.001, I2=69%
Test for overall eect: z=3.41, P<0.001
Test for subgroup dierences: χ2=22.14, df=1, P<0.001, I2=95.5%
1.05 (0.86 to 1.29)
0.92 (0.44 to 1.92)
0.90 (0.72 to 1.14)
0.98 (0.85 to 1.14)
1.86 (1.39 to 2.47)
1.79 (1.13 to 2.82)
1.73 (1.27 to 2.35)
1.70 (1.23 to 2.33)
1.55 (1.06 to 2.27)
1.31 (0.73 to 2.33)
1.29 (1.04 to 1.59)
1.56 (1.38 to 1.75)
1.37 (1.14 to 1.64)
13.4
4.4
12.7
30.4
11.4
7.9
10.9
10.7
9.4
6.1
13.2
69.6
100.0
0.5 0.7 1 1.5 2
Study or subgroup
Favours
medical care
Favours endovascular
treatment
(including AIMT)
Risk ratio (95% CI)
 M-H, random
Risk ratio (95% CI)
 M-H, random
Weight
(%)
177/434
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265/679
89/164
25/35
77/233
59/98
45/103
19/55
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417/878
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Endovascular treatment
(including AIMT)
86/222
11/54
84/181
181/457
43/147
14/35
51/267
33/93
29/103
14/53
82/195
266/893
447/1350
Medical
care
No of events/total
fig 3 | forest plot for a good functional outcome (modified rankin scale core ≤2) at 90 days, including subgroup analysis 
by year of study publication. aimt=adjunctive intra-arterial mechanical thrombectomy
2013
  IMS III
  MR RESCUE
  SYNTHESIS
Subtotal (95% CI)
Test for heterogeneity: τ2=0.02, χ2=2.58, df=2, P=0.28, I2=22%
Test for overall eect: z=0.11, P=0.92
2015
  EXTEND-IA
  ESCAPE
  MR CLEAN
  SWIFT PRIME
  REVASCAT
  THRACE
  THERAPY
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00, χ2=5.10, df=9, P=0.53, I2=0%
Test for overall eect: z=1.40, P=0.16
Total (95% CI)
Test for heterogeneity: τ2=0.00, χ2=8.15, df=9, P=0.52, I2=0%
Test for overall eect: z=z=1.24, P=0.22
Test for subgroup dierences: χ2=0.49, df=1, P=0.48, I2=0%
0.89 (0.65 to 1.22)
0.78 (0.39 to 1.56)
1.44 (0.82 to 2.54)
0.98 (0.72 to 1.35)
0.43 (0.12 to 1.52)
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13/54
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26/195
11/53
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fig 4 | forest plot for mortality at 90 days, including subgroup analysis by year of study publication. aimt=adjunctive 
intra-arterial mechanical thrombectomy
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pooled results of studies, but not for pooled results of 
studies published in 2013 (I2=0%; P=0.62) and in 2015 
(I2=0%; P=0.43), which further support our a priori 
hypothesis that heterogeneity would exist between the 
results of trials done in 2013 and those done in 2015 
owing to inequalities in study design, including patient 
populations and interventions. Indeed, the results for 
efficacy outcomes were significantly different (P<0.001) 
between these two subgroups of trials. No differences 
were found in the proportion of patients reaching mod-
ified Rankin scale scores of ≤2 (fig 3) or ≤1 (supplemen-
tary figure S1) among 2013 trials. In contrast, the pooled 
risk ratio for 2015 trials was 1.56 (95% confidence inter-
val 1.38 to 1.75), representing an increase of 167 patients 
(95% confidence interval 113 to 223 patients) attaining a 
good outcome (modified Rankin scale score ≤2) for each 
1000 additional patients receiving endovascular treat-
ment compared with medical care alone. Additionally, 
the pooled risk ratio for 2015 trials for a modified Rankin 
scale score of ≤1 (supplementary figure S1) was 2.03 
(95% confidence interval 1.62 to 2.53; I2=0, P=0.99), rep-
resenting an increase of 131 patients (79 to 195 patients) 
attaining an excellent outcome for each 1000 additional 
patients receiving endovascular treatment compared 
with medical care alone. Data on outcomes for THRACE 
and THERAPY are not yet completely published. Sensi-
tivity analysis excluding these studies from pooled risk 
ratio for 2015 trials yielded similar results: modified 
Rankin scale scores ≤2 (risk ratio 1.73, 95% confidence 
interval 1.49 to 2.01; I2=0, P=0.97) and ≤1 (2.04, 1.62 to 
2.58; I2=0, P=0.99). Further sensitivity analysis exclud-
ing trials with low rates of patients treated with intrave-
nous rt-PA in the control arm (MR RESCUE) or with low 
rates of adjunctive intra-arterial mechanical thrombec-
tomy in the endovascular treatment arm (IMS III and 
SYNTHESIS) also yielded similar results for all efficacy 
outcomes; all these trials were published in 2013.
At 90 days, 482 out of 2880 participants (16.7%) died, 
without differences between arms in all cause mortality 
(risk ratio 0.90, 95% confidence interval 0.76 to 1.06; 
I2=0%, P=0.52; fig 4). Furthermore, the results did not 
differ between trials published in 2013 and 2015 
(P=0.48). Sensitivity analysis excluding THRACE and 
THERAPY from the pooled risk ratio for 2015 trials 
yielded similar results (0.87, 0.68 to 1.11; I2=0%, P=0.43).
Overall, 129 out of 2526 patients (5.1%) experienced 
symptomatic intracerebral haemorrhage, with no sig-
nificant differences between treatment groups (risk 
ratio 1.02, 95% confidence interval 0.72 to 1.44; I2=0%, 
P=0.85; supplementary figure S2). Furthermore, there 
were no significant differences between the results of 
trials published in 2013 and 2015 (P=0.86). Sensitivity 
analysis excluding THERAPY from the pooled risk ratio 
for 2015 trials yielded similar results (1.08, 0.63 to 1.83; 
I2= 0%, P=0.48).
additional analysis
The number of included studies limited the evaluation 
of publication bias using funnel plots. Egger’s (P=0.435) 
and Peters’ (P=0.483) tests were not suggestive of publi-
cation bias or small studies’ effects.
For the trial sequential analysis, the proportion of 
patients with a favourable outcome (modified Rankin 
scale score ≤2) was 33%, and an increase in risk ratio 
of 37% was assumed based on the risk ratio of 1.37 
estimated for the independency outcome. The cumu-
lative evidence overcame the minimum information 
size required (1873 patients), adjusted for the obtained 
increase in risk ratio and heterogeneity (see supple-
mentary figure S3). The cumulative evidence was not 
adequately powered for evaluation of mortality, 
reaching 20.1% of the required information size for a 
9% risk ratio reduction of mortality (see supplemen-
tary figure S4).
Predetermined subgroup analysis for the primary 
efficacy outcome based on sex (see supplementary fig-
ure S5) and administered intravenous rt-PA across all 
patients (rt-PA versus no rt-PA; supplementary figure 
S6) was not significant between subgroups (P=0.61 and 
P=0.05, respectively).
Subgroup analysis according to stent retriever use 
reached significance (P=0.04; supplementary figure 
S7), favouring high (≥85%) stent retriever use (risk ratio 
1.69, 95% confidence interval 1.42 to 2.01) over low to no 
use (1.18, 0.88 to 1.58).
Subgroup analysis according to risk of bias, charac-
teristics of stroke, and time to treatment were not 
done because of the similar risk of bias across studies 
and because of lack of robust data for strokes involv-
ing the posterior circulation and time to endovascular 
treatment.
discussion
In this systematic review we found that there is moder-
ate to high quality evidence suggesting that the addi-
tion of endovascular treatment, in particular 
thrombectomy with stent retriever, to best medical care 
including intravenous rt-PA, improves the probability of 
a patient being functionally independent at 90 days 
after ischaemic stroke, without increased mortality or 
symptomatic intracerebral haemorrhage.
These conclusions are based on 10 randomised con-
trolled trials enrolling 2925 patients with ischaemic 
stroke. Although pooled analysis of these trials yielded 
statistically significant and clinically relevant effects, 
statistically significant heterogeneity was found 
among the results of the studies. This heterogeneity 
was driven by differences in methodological and clini-
cal features between studies. There were disparities in 
inclusion criteria and in the interventions considered 
in both the standard medical treatment and the endo-
vascular treatment arms; in particular, the proportion 
of patients who underwent intravenous thrombolysis 
and adjunctive intra-arterial mechanical thrombec-
tomy, as well as the type of devices used for thrombec-
tomy. These differences led us to look at the results of 
the 10 included randomised controlled trials sepa-
rately, using two distinct subgroups: trials published in 
2013, including IMS III, SYNTHESIS, and MR RESCUE, 
and trials published in 2015, including MR CLEAN, 
ESCAPE, EXTEND-IA, SWIFT-PRIME, REVASCAT, 
THERAPY, and THRACE.
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All the studies focused on strokes involving the ante-
rior circulation, but IMS II, SYNTHESIS, and THRACE 
also included strokes in the posterior circulation as 
part of their inclusion criteria. THRACE also included 
strokes involving the proximal artery (internal carotid 
or M1). The former were the only types of strokes 
included in REVASCAT and SWIFT-PRIME. ESCAPE, 
MR CLEAN, REVASCAT, SWIFT-PRIME, and THERAPY 
also included strokes of the M2 portion of the middle 
cerebral artery.
Imaging evidence of large vessel occlusion (the index 
problem amenable by thrombectomy) was not required 
for enrolment in IMS III and SYNTHESIS but was an 
obligatory criterion in MR RESCUE and in all 2015 stud-
ies. In four studies it was also needed to document 
potentially salvageable brain tissue: perfusion imaging 
showing evidence of penumbra was required in three of 
the 2015 studies (ESCAPE, EXTEND-IA, and SWIFT 
PRIME), and REVASCAT only included patients with a 
high ASPECTS score—that is, with imaging features 
suggestive of less extensive brain damage. Although MR 
RESCUE evaluated the existence of penumbra, this was 
not a criterion for enrolment.
Most patients in the medical care arm (>77%) were 
treated with intravenous rt-PA (the only exception being 
MR RESCUE) as well as in the endovascular treatment 
arm (>68% of the patients), except in SYNTHESIS and 
MR RESCUE (where the rate of administered intrave-
nous thrombolysis was low). In IMS III the dose of intra-
venous rt-PA was reduced because of the study design 
and safety issues.
Although all studies evaluated patients subjected to 
thrombectomy in the endovascular arm, the rate of 
patients who underwent adjunctive intra-arterial 
mechanical thrombectomy varied between studies. In 
2015 trials this rate was high (>77%). However, less than 
40% of the patients were treated with thrombectomy in 
IMS III and SYNTHESIS but were given intra-arterial 
rt-PA, a strategy that has proved to be of little benefit 
because of an increase in complications.48  Also import-
ant, the use of stent retrievers was more prominent in 
the most recent trials, which were the studies with the 
highest rates for reperfusion. Solitaire FR, the most 
commonly used stent retriever, is a newer generation 
device that has been shown to contribute to higher reca-
nalisation rates and reduced deployment times com-
pared with previous devices.49  The use of outdated first 
generation devices may have led to the suboptimal 
revascularisation rates observed in IMS III and MR RES-
CUE (41% and 25%, respectively) and, at least in IMS III, 
may have contributed to substandard groin puncture to 
reperfusion times.50
The focus on large vessel occlusion scenarios, the 
selection of patients with less extensive brain tissue 
damage, the use of two simultaneous endovascular 
reperfusion techniques (intravenous rt-PA and throm-
bectomy), and the use of more efficient devices are 
probably pivotal factors that help to explain the differ-
ence between the statistically significant and clini-
cally relevant results observed among the 2015 
randomised controlled trials, but not among the 2013 
trials. Unsurprisingly, some previous systematic 
reviews and meta-analyses focusing mainly on 2013 
publications9 10 12  failed to detect differences between 
treatments. However, our results are supported by the 
quantitative analysis of current meta-analytical stud-
ies that include more recent published randomised 
controlled trials.51 52 53
Considering the pathophysiology of ischaemic stroke 
and the knowledge acquired from IMS III54  and SYN-
THESIS,55  as well as from previous trials of rt-PA,6 it can 
be concluded that faster, more efficient recanalisation 
is of paramount importance to reduce the infarction of 
penumbral brain tissue and thus contribute to 
improved clinical outcomes. As such, the prompt 
administering of intravenous rt-PA as well as timely 
intravascular intervention achieved in 2015 studies may 
have contributed to less brain tissue damage.
Because of the reasons discussed previously and 
the rate and dosage of intravenous rt-PA used in both 
study arms, the trials published or presented in 2015 
are more suited to test the true effect of endovascular 
thrombectomy on its index disease. We therefore con-
sider that pooled results from these studies evaluate 
more  accurately the benefit of endovascular treat-
ment in general and adjunctive thrombectomy after 
intravenous rt-PA in particular, for ischaemic stroke 
caused by large vessel occlusion. Based on these 
results, we conclude that patients undergoing 
adjunctive intra-arterial mechanical thrombectomy 
are twice as likely to be without disability and 1.5 
times as likely to be functionally independent 90 
days after an ischaemic stroke caused by occlusion of 
anterior large vessels.
weaknesses of this study
Despite using data from multicentre randomised con-
trolled trials, the information was not powered enough 
to evaluate the safety of endovascular treatment, 
including adjunctive intra-arterial mechanical throm-
bectomy. Furthermore, observational studies may be 
more adequate than randomised controlled trials to 
evaluate safety, as these may include patients who are 
usually excluded from randomised controlled trials, 
and follow-up is often longer. Lastly, the magnitude of 
effects may have been exaggerated by stricter patient 
selection and by a higher level of study site selection 
and interventionist proficiency compared with the real 
world.
The prospective randomised open blinded endpoint 
design of all studies has greater similarities with every-
day clinical practice and is more cost effective than dou-
ble blinded randomised controlled trial designs.56  None 
the less, such studies eliminate a placebo effect—a phe-
nomenon not discarded in blind sham controlled tri-
als—and are more likely to lead to researcher and 
patient biases56 and to patient drop-out after randomis-
ation.
In stroke trials it is customary to provide outcomes at 
90 days.57  However, spontaneous neurological recov-
ery may take longer to attain its maximal potential,57 so 
longer follow-ups could have contributed to a better 
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understanding of the evolution of functional endpoints 
through time.
Another limitation was the overall moderate risk of 
bias—all the trials used the prospective randomised 
open blinded endpoint design, some were mostly 
funded by industry, six were stopped early, and one was 
registered retrospectively. Nevertheless, previous 
reports noted that industry sponsored studies can accu-
rately report outcomes58  and that efficacy treatment 
effects in truncated trials may not be substantially 
larger than for completed trials.59 Finally, data from the 
THRACE and THERAPY trials have not yet been offi-
cially published. These data was extracted from scien-
tific conferences and press releases. Therefore it is 
possible that the available information is not definitive.
implications for clinical practice
Recommending endovascular treatment, particularly 
adjunctive intra-arterial mechanical thrombectomy with 
stent retrievers, as standard of care in ischaemic stroke 
caused by occlusion of large vessels in the anterior circu-
lation requires a restructuring of comprehensive stroke 
centres and of interventional neuroradiologists’ training 
to enhance the available resources.
The baseline characteristics of the included popula-
tion mean that the pooled clinical benefit attributable 
to adjunctive intra-arterial mechanical thrombectomy 
may only be applicable to patients younger than 85 
years with strokes involving the large vessels of the 
anterior circulation where brain damage is not wide-
spread and if the intervention is performed within six to 
eight hours after an acute stroke. Adding thrombectomy 
to standard intravenous rt-PA opens the conventional 
treatment window from 4.5 hours to at least six hours in 
these scenarios. Still, the decision to use adjunctive 
thrombectomy should be taken shortly after patients 
start to receive intravenous rt-PA.
implications for research
Future studies should evaluate the optimal timeframe 
for adjunctive intra-arterial mechanical thrombectomy; 
its benefit in patients with contraindications to throm-
bolysis, strokes involving the posterior circulation, and 
older populations; and its safety profile. Also, longer 
follow-ups could help provide a better understanding 
of the cost effectiveness and impact on budgets of 
implementing adjunctive intra-arterial mechanical 
thrombectomy. Finally, cost effectiveness analyses 
should be pursued to ascertain the value of endovascu-
lar thrombectomy before the widespread implementa-
tion and restructuring of comprehensive stroke centres.
Conclusion
In contrast with some previous publications8 9 11  and the 
results obtained in initial trials, this systematic review 
and meta-analysis found that endovascular treatment, 
in particular thrombectomy as an add-on to intrave-
nous rt-PA, provides beneficial functional outcomes 
after ischaemic stroke secondary to occlusion of ante-
rior large vessels, without increased detrimental effects 
compared with medical care alone. Our results and rec-
ommendations are in accordance with other recently 
published systematic reviews in this specialty.51-53 In 
addition to the studies already included in those recent 
systematic reviews, we included data from two unpub-
lished studies and performed a cumulative meta-ana-
lytical measurement—trial sequential analysis—that 
reinforces our findings and recommendations. Also, our 
qualitative analysis allows for an indepth view of the 
clinical and methodological disparities between the 
published trials. This, in turn, helps to explain the shift 
in evidence regarding endovascular thrombectomy in 
acute stroke as well as to explore the clinical contexts 
where this invasive approach seems to be more benefi-
cial. We think that the critical discussion on how the 
obtained results translate into clinical practice is of par-
ticular interest to both neurologists and neuroradiolo-
gists when deciding the best treatment option for 
individual patients with acute stroke.
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